期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status 被引量:6
1
作者 Toshihiro Inokuchi Jun Kato +8 位作者 Sakiko Hiraoka Hideyuki Suzuki Asuka Nakarai tomoko hirakawa Mitsuhiro Akita Sakuma Takahashi Keita Harada Hiroyuki Okada Kazuhide Yamamoto 《World Journal of Gastroenterology》 SCIE CAS 2014年第2期509-517,共9页
AIM:To clarify the impact of cytomegalovirus(CMV)activation and antiviral therapy based on CMV antigen status on the long-term clinical course of ulcerative colitis(UC)patients.METHODS:UC patients with flare-up were d... AIM:To clarify the impact of cytomegalovirus(CMV)activation and antiviral therapy based on CMV antigen status on the long-term clinical course of ulcerative colitis(UC)patients.METHODS:UC patients with flare-up were divided into CMV-positive and-negative groups according to the CMV antigenemia assay.The main treatment strategy provided for the patients in the CMV-positive group comprised a dose reduction of corticosteroids and administration of ganciclovir.RESULTS:The median number of days to initial remission was significantly greater for the patients in the CMV-positive group(21 d vs 16 d,P=0.009).However,the relapse rate after remission and colectomy rate during more than 30 mo of observation did not differ between the two groups.Multivariate analysis revealed that administration of ganciclovir was the only independent factor for avoiding colectomy in patients of the CMV-positive group.CONCLUSION:CMV antigen status did not significantly affect the long-term prognosis in UC patients under treatment with appropriate antiviral therapy. 展开更多
关键词 ULCERATIVE COLITIS CYTOMEGALOVIRUS CYTOMEGALOVIRUS
下载PDF
Disparity in clinical care for patients with inflammatory bowel disease between specialists and non-specialists
2
作者 tomoko hirakawa Jun Kato +7 位作者 Sakuma Takahashi Hideyuki Suzuki Mitsuhiro Akita Izumi Inoue Hisanobu Deguchi Sakiko Hiraoka Hiroyuki Okada Kazuhide Yamamoto 《Open Journal of Gastroenterology》 2013年第1期64-71,共8页
Background: Although inflammatory bowel disease (IBD) patients have been increasing and new thera-peutic options for IBD have been developed, there are relatively few clinicians who specialize in IBD. Patients treated... Background: Although inflammatory bowel disease (IBD) patients have been increasing and new thera-peutic options for IBD have been developed, there are relatively few clinicians who specialize in IBD. Patients treated by a non-specialist of IBD may not receive appropriate treatment. This study aimed to compare disease and medication status between IBD patients treated by a specialist and those treated by a non-specialist. Methods: Medical charts of ambulating IBD patients in two hospitals were examined. All patients in one hospital were treated by one of the IBD specialists, while in the other hospital, patients were treated by one of the gastroenterologists who was a non-specialist of IBD. Results: The numbers of IBD patients were 255 (hospital with specialists) and 74 (hospital without specialists), respectively. Disease activity of the patients was not well-controlled in the hospital without specialists compared to in the hospi- tal with specialists (ulcerative colitis (UC): p = 0.0006 and Crohn’s disease: p = 0.012, respectively). The proportion of UC patients who received an insufficient dose of mesalazine (Pentasa < 3 g/day or Asacol < 3.6 g/day) was higher in the hospital without specialists (47% vs. 15%, p < 0.0001). In the hospital without specialists, more patients received long-term corticosteroids (UC: 23% vs. 5%, p < 0.0001), while fewer patients received immunomodulators (UC: 8% vs. 46%, p < 0.0001). Conclusions: IBD patients of the hospital without specialists were not well-controlled and were not prescribed appropriately with thera-peutic drugs. Fostering and placement of the specialist of IBD is an urgent problem. 展开更多
关键词 INFLAMMATORY BOWEL Disease Clinical Care SPECIALIST
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部